CJC-1295 Ipamorelin Blend
Price range: £83.00 through £135.00
🧪 CJC-1295 / Ipamorelin Blend – 5mg/5mg – 10mg/10mg per vial
✅ ≥99% Purity – HPLC verified with COA available
🧊 Free Bac Water – Included with every order
📦 10 Vials – Per order for extended research
🚚 Fast Shipping – Discreet packaging with tracking
🔬 Research Grade – Strict quality control protocols
⚠️ Research Use Only – Not for human consumption
15% DISCOUNT ON CHECKOUT WITH CRYPTO
- Satisfaction Guaranteed
- No Hassle Refunds
- Secure Payments
Description
CJC-1295 Ipamorelin – Premium Research Peptide Blend
What Is CJC-1295 Ipamorelin?
CJC-1295 Ipamorelin is a synergistic peptide combination that pairs a growth hormone-releasing hormone (GHRH) analogue with a selective ghrelin receptor agonist. This dual-pathway research blend targets two distinct receptor systems on pituitary somatotroph cells, providing a defined tool for investigating growth hormone axis modulation in laboratory settings.
The CJC-1295 component functions as a synthetic analogue of GHRH, binding and activating the GHRH receptor to stimulate growth hormone synthesis and release. The Ipamorelin component acts as a selective agonist at the ghrelin/growth hormone secretagogue receptor (GHSR-1a), triggering rapid release of stored growth hormone. This receptor-level separation is what makes the pairing mechanistically informative rather than redundant—researchers can examine convergent versus independent signalling within a single experimental system.
Foundational research by Bowers and colleagues demonstrated that combining GHRH with a ghrelin mimetic produces synergistic GH responses exceeding the sum of either compound alone, a finding that underpins the rationale for studying this CJC 1295 Ipamorelin combination.
Product Specifications
| Feature | Specification |
|---|---|
| Product Name | CJC-1295 Ipamorelin Blend |
| Components | CJC-1295 (No DAC) + Ipamorelin |
| Ratio | 5mg / 5mg per vial (10mg total) |
| Purity | ≥99% (HPLC verified per component) |
| Form | Lyophilised powder |
| Storage | -20°C (long-term) |
| For Research Use Only | Not for human or veterinary use |
Research Applications
Growth Hormone Axis Pharmacology
This blend is studied for its dual action on the hypothalamic-pituitary-somatotropic axis. The CJC 1295 component activates GHRH receptors on pituitary somatotrophs, while Ipamorelin engages the ghrelin receptor on the same cells. Research published in the American Journal of Physiology demonstrated that once-daily administration of CJC-1295 normalized growth parameters and body composition in GHRH knockout mouse models, with effects reduced when dosing intervals were extended.
Pulsatile GH Secretion Research
A key area of CJC 1295 Ipamorelin research involves pulsatile growth hormone secretion. Studies by Ionescu and Frohman established that pulsatile GH secretion persists during continuous stimulation by CJC-1295, a finding with important implications for understanding neuroendocrine feedback regulation. Human pharmacology data for CJC-1295 is indexed on PubMed, documenting dose-dependent GH elevations in healthy adult volunteers.
Selective GH Release Mechanisms
Ipamorelin’s defining characteristic among growth hormone secretagogues is its selectivity profile. A 1998 preclinical study by Raun and colleagues, available through Europe PMC, demonstrated that Ipamorelin released GH at levels comparable to GHRP-6 without the cortisol, prolactin, or ACTH release observed with earlier secretagogues. This selectivity makes the combination relevant for research requiring GH axis specificity without HPA axis activation.
Metabolic and Body Composition Studies
Research involving this blend often investigates IGF-1 as the primary downstream effector of pulsatile GH release. A clinical review in Sage Journals examined the therapeutic landscape of injectable peptides including CJC-1295, providing context for laboratory investigations of metabolic signalling.
Somatotroph Proliferation Research
Additional preclinical work indexed through Johns Hopkins University examined the effects of CJC-1295 on somatotroph proliferation and growth hormone axis recovery in knockout models, offering a mechanistic foundation for studies using the CJC 1295 Ipamorelin combination.
Quality and Purity
Each batch of CJC 1295 Ipamorelin undergoes rigorous quality control testing to ensure:
-
≥99% purity verified by HPLC for each component
-
Correct molecular weight confirmed by mass spectrometry
-
Consistent peptide content validated by amino acid analysis
Certificates of Analysis (COA) are available upon request, providing lot-specific documentation for both components.
Frequently Asked Questions
What is CJC-1295 Ipamorelin?
CJC-1295 Ipamorelin is a research peptide blend containing CJC-1295 (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist) used for laboratory investigation of growth hormone axis signalling.
How does the blend work?
The combination targets two distinct receptor systems on pituitary cells. CJC 1295 activates GHRH receptors to stimulate GH synthesis, while Ipamorelin engages ghrelin receptors to trigger rapid GH release, as documented in the Ipamorelin selectivity literature.
What is the difference between CJC-1295 with and without DAC?
CJC 1295 with DAC binds serum albumin, extending its half-life to approximately 5.8–8.1 days. CJC 1295 without DAC has a shorter half-life supporting a more pulsatile pharmacokinetic profile. This blend uses the no-DAC variant.
Is CJC-1295 Ipamorelin legal in the UK?
Neither compound is controlled under the Misuse of Drugs Act 1971, and both are legal to supply as research compounds. However, neither holds a UK marketing authorisation, and supply for human use is unlawful under the Human Medicines Regulations 2012. Both are also prohibited substances under the WADA Prohibited List adopted by UK Anti-Doping.
What purity level can I expect?
Our product is provided at ≥99% purity for each component, verified by HPLC.
How should it be stored?
Store at -20°C for long-term stability. Lyophilised powder should be reconstituted according to standard laboratory protocols.
Is there human clinical trial data?
CJC-1295 has been studied in healthy adult volunteers, with results available via PubMed. No published human trial has tested the specific combination with Ipamorelin.
Conclusion
This blend is a well-characterized research combination for laboratories investigating growth hormone axis pharmacology, dual-receptor signalling, and pulsatile GH secretion. With CJC-1295 and Ipamorelin combined in a defined 5mg/5mg format, the CJC-1295 Ipamorelin blend enables mechanistic studies on GHRH receptor activation, ghrelin receptor agonism, and downstream endocrine regulation.
For researchers requiring a reliable, high-purity blend for their studies, Cocer Peptides provides lab-tested compounds with Certificates of Analysis available upon request.
Ready to Advance Your Research?
Order premium CJC-1295 Ipamorelin for your research today. Contact our team for COA requests or technical inquiries.
Additional information
| mg | 10/10mg, 5/5mg |
|---|






Reviews
There are no reviews yet.